Status:
ENROLLING_BY_INVITATION
to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection
Lead Sponsor:
Kaohsiung Medical University
Collaborating Sponsors:
An-Nan Hospital, China Medical University
Conditions:
HELICOBACTER PYLORI INFECTIONS
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan
Eligibility Criteria
Inclusion
- Subjects infected with Helicobacter pylori.
Exclusion
- Those who are allergic to the drugs used in this research.
- Those who have had stomach surgery.
- Those with severe liver cirrhosis or uremia or malignant tumors.
- Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.
Key Trial Info
Start Date :
September 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07142798
Start Date
September 26 2024
End Date
January 31 2026
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807